To the point
Omics Express is a community-supported bioinformatic software project, and a consultancy.
We specialize in:
Our software projects have a successful track record in assisting important scientific and industrial breakthroughs.
FDA news on personalized medicine: FDA Approves Kalydeco to Treat Rare Form of Cystic Fibrosis
The U.S. Food and Drug Administration today approved Kalydeco (ivacaftor) for the treatment of a rare form of cystic fibrosis (CF) in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene.
CF is a serious genetic disorder affecting the lungs and other organs that ultimately leads to an early death. It is caused by mutations (defects) in a gene that encodes for a protein called CFTR that regulates ion (such as chloride) and water transport in the body. The defect in chloride and water transport results in the formation of thick mucus that builds up in the lungs, digestive tract and other parts of the body leading to severe respiratory and digestive problems, as well as other complications such as infections and diabetes.
Our software tools have contributed to significant amount of scientific
and commercial successes. These include:
Successful identification of the human IL28B variation - a biomarker for hepatitis C treatment efficacy. This scientific breakthrough was published in Nature in 2009, and the resulted clinical diagnostic service has been provided to benefit the hepatitis C patients.